拉坦前列腺素(适利达)对降低难治性青光眼眼内压的疗效观察  

A clinical observation on Xalatan in treating patients with refractory glaucoma

作　　者：吴燕 肖建江 沈秋杰 

机构地区：[1]江苏省宜兴市第二人民医院,江苏宜兴214221

出　　处：《现代预防医学》2012年第21期5776-5777,共2页Modern Preventive Medicine

摘　　要：目的观察拉坦前列腺素(适利达)对降低难治性青光眼眼内压的临床疗效。方法选取2009年1月～2011年12月某院诊治的难治性青光眼32例(32眼),给予适利达滴眼液点眼,每日1次。分别于要用药前和用药后1周、4周、8周、12周测定患者眼压和视力,记录其不良反应。结果与用药前相比,适利达滴眼液点眼后患者眼压明显降低,差异具有统计学意义(P﹤0.05);不同时间点眼压降低幅度比较差异无统计学意义(P﹥0.05);用药前后患者视力获轻微改善,但差异无统计学意义(P﹥0.05)。结论拉坦前列腺素(适利达)对降低难治性青光眼眼内压的临床疗效确切,无严重不良反应。OBJECTIVE To evaluate the effect of Xalatan in treating patients with refractory glaucoma.METHODS Selected 32 cases of patients with refractory glaucoma from January 2009 to December 2012 in our hospital,treated with Xalatan eyedrops once daily.Measured intraocular pressure（IOP） at 1,4,8 and 12 weeks later,and compared with the baseline.Recorded the adverse reactions.RESULTS Compared with the baseline,the intraocular pressure was obviously reduced after Xalatan treatment,the differences were statistically significant（P ﹤ 0.05） ;reduction of intraocular pressures at different time points were not statistically significant（P﹥0.05）;the patients＇ vision improved mildly before and after the medication,but the difference was not statistically significant（P﹥0.05）.CONCLUSION Xalatan can obviously reduce intraocular pressure of patients with refractory glaucoma and without serious adverse reactions.

关 键 词：拉坦前列腺素 难治性青光眼 眼内压 

分 类 号：R775[医药卫生—眼科]